News Release

October 24, 2024
Perseus Proteomics, Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Announcement of Presentation of PPMX-T002 at EANM'24 Annual Congress

Perseus Proteomics Inc. ("the Company") is pleased to announce that the poster of PPMX-T002, a radioisotope labelled antibody under development led by the Company, was presented at the EANM (European Association of Nuclear Medicine)'24 in Hamburg, Germany.

Title:	Preclinical evaluation of Cadherin 3 (CDH3)-targeted alpha radiopharmaceutical therapy, ^{225}Ac-PPMX-T002 for the treatment of solid cancer
Date:	October 19 – 23, 2024

PPMX-T002 is a radioisotope labelled antibody against cadherin 3 (CDH3), which is expressed on solid tumors including head and neck, ovarian, pancreatic and lung cancers. The Company has been developing the antibody under a strategy to change the radioisotope from Yttrium 90 (^{90}Y), a beta emitter, to Actinium 225 (^{225}Ac), an alpha emitter. In the animal experiments using mice with human pancreatic cancer cells transplanted, it was shown that ^{225}Ac-labelled antibody exhibited more remarkable efficacy compared with ^{90}Y-labelled antibody.

END